drugset / Trial / NCT01114048
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
NaSingle-groupOpen-labelTreatment
Summary
In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone) and early intensification of Vel-CD (bortezomib and CD) as induction chemotherapy followed by autologous stem cell transplantation for the patients with newly diagnosed multiple myeloma.
Timeline
- Start
- 2010-03
- Primary completion
- 2012-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 150 mg/m2 | Oral |
| Subject | Dexamethasone | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Thalidomide | Other / unclassified | 50 mg | Oral |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
| Background | Acyclovir | Small molecule | — | — |
| Background | Aspirin | Small molecule | — | — |
| Background | trimethoprim-sulfamethoxazole | Unknown | — | — |